Clinical and bacteriological efficacy of twice daily topical retapamulin ointment 1% in the management of impetigo and other uncomplicated superficial skin infections

Benjamin R Bohaty, Sangbum Choi, Chunyan Cai, Adelaide A Hebert, Benjamin R Bohaty, Sangbum Choi, Chunyan Cai, Adelaide A Hebert

Abstract

Background: Cutaneous bacterial infections are common in children and adults and frequently are caused by Staphylococcus aureus (S. aureus). Treatment failures with topical agents are not uncommon and have been shown to be secondary to bacterial resistance.

Objective: To determine clinical and bacteriological efficacy of retapamulin ointment 1% in treatment of patients with cutaneous bacterial infections caused by methicillin-resistant S. aureus (MRSA) and other bacteria.

Methods: Prospective, nonrandomized, uncontrolled, open label, single center trial conducted between April 2008 and November 2012 that evaluated efficacy of retapamulin ointment 1% in the treatment of impetigo, folliculitis, and other minor soft tissue infections in children and adults. Fifty patients, who presented to a dermatology outpatient clinic and were clinically diagnosed with impetigo, folliculitis, or minor soft tissue infection suitable for treatment with a topical antibiotic, were screened. Thirty-eight patients were enrolled and received treatment: topical retapamulin ointment 1% twice daily for 5 days. Seven patients were MRSA positive and qualified for the primary efficacy population. One patient withdrew due to an adverse event. Clinical and microbiological exams were performed at baseline and follow-up 5 to 7 days later to assess clinical, microbiological, and therapeutic responses. Primary outcome was clinical response at follow-up in primary efficacy population with MRSA isolated as the baseline pathogen. Secondary outcomes included clinical, microbiologic, and therapeutic responses in patients who were culture positive for any species of bacteria.

Results: Clinical response at follow-up in the primary efficacy population (MRSA-positive patients) was not sufficiently powered to demonstrate significance; however, outcomes were excellent, with 7 of 7 patients demonstrating clinical success (5 of 7) or clinical improvement (2 of 7) at follow-up. Barring lack of significance due to small total sample size for patients who were culture positive for any species of bacteria (n = 35), overall success rates were favorable for clinical, microbiologic, and therapeutic responses with values of 66%, 97%, and 69%, respectively. Adverse events (AEs) were mild or moderate in severity. No serious AEs were reported.

Conclusion: Safety profile appears favorable given the low number of AEs. Study design limits conclusions that can be drawn. Nevertheless, this study supports use of topical retapamulin 1% ointment in treatment of cutaneous bacterial infections, particularly those caused by S. aureus, including MRSA.

Keywords: Impetigo; MRSA; MSSA; Pediatric; Retapamulin.

Figures

Fig. 1
Fig. 1
Flow diagram of patient progress throughout the trial: CLI = all patients enrolled in the study who received at least 1 application of study medication, MIC = all patients in CLI who had a pathogen isolated from the treatment area at baseline upon microbiologic testing, and RES = all patients in CLI who had MRSA isolated as a baseline pathogen (primary efficacy population).

References

    1. Bangert S., Levy M., Hebert A.A. Bacterial resistance and impetigo treatment trends: a review. Pediatr Dermatol. 2012;29:243–248.
    1. Bernard P. Management of common bacterial infections of the skin. Curr Opin Infect Dis. 2008;21:122–128.
    1. Clinical and Laboratory Standards Institute . Seventeenth Informational Supplement. CLSI; Wayne, PA: 2007. Performance Standards for Antimicrobial Susceptibility Testing. (CLSI Document M100-S17)
    1. Cole C., Gazewood J. Diagnosis and treatment of impetigo. Am Fam Physician. 2007;75:859–864.
    1. Darmstadt G.L., Lane A.T. Impetigo: an overview. Pediatr Dermatol. 1994;11:293–303.
    1. Deshpande L.M., Fix A.M., Pfaller M.A., Jones R.N., SENTRY Antimicrobial Surveillance Program Participants Group Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis. 2002;42:283–290.
    1. Dhingra D., Parakh A., Ramachandran S. Retapamulin: a newer topical antibiotic. J Postgrad Med. 2013;59:127–130.
    1. Durupt F., Mayor L., Bes M., Reverdy M.E., Vandenesch F., Thomas L. Prevalence of Staphylococcus aureus toxins and nasal carriage in furuncles and impetigo. Br J Dermatol. 2007;157:1161–1167.
    1. George A., Rubin G. A systematic review and metaanalysis of treatments for impetigo. Br J Gen Pract. 2003;53:480–487.
    1. GlaxoSmithKline . GlaxoSmithKline; Research Triangle Park, NC: 2007. ALTABAX prescribing information.
    1. Gorwitz R.J. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and update. Pediatr Infect Dis J. 2008;27:925–926.
    1. Habif T. 4th ed. Mosby, Inc; Philadelphia: 2004. Bacterial infections. Clinical dermatology.
    1. Johnsson D., Mölling P., Strålin K., Söderquist B. Detection of Panton-Valentine leukocidin gene in Staphylococcus aureus by LightCycler PCR: clinical and epidemiological aspects. Clin Microbiol Infect. 2004;10:884–889.
    1. Kaplan S.L. Commentary: prevention of recurrent staphylococcal infections. Pediatr Infect Dis J. 2008;27:935–937.
    1. Kaplan S.L., Hulten K.G., Gonzalez B.E., Hammerman W.A., Lamberth L., Versalovic J. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis. 2005;40:1785–1791.
    1. Kaplan S.L., Forbes A., Hammerman W.A., Lamberth L., Hulten K.G., Minard C.G. Randomized trial of “bleach baths” plus routine hygienic measures vs routine hygienic measures alone for prevention of recurrent infections. Clin Infect Dis. 2014;58:679–682.
    1. Koning S., van der Sande R., Verhagen A.P., van Suijlekom-Smit L.W.A., Morris A.D., Butler C.C., Berger M., van der Wouden J.C. Interventions for impetigo. Cochrane Database of Systematic Reviews. 2012;1 Art. No.: CD003261.
    1. Lee S.Y., Kuti J.L., Nicolau D.P. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt) 2005;6:283–295.
    1. Lina G., Piemont Y., Godail-Gamot F., Bes M., Peter M.O., Gauduchon V. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 1999;29:1128–1132.
    1. McNeal J.C., Hulten K.G., Kaplan S.L., Mason E.O. Decreased susceptibilities to retapamulin, mupirocin, and chlorhexidine among staphylococcus aureus isolates causing skin and soft tissue infections in otherwise healthy children. Antimicrob Agents Chemother. 2014;58:2878–2883.
    1. Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., Carey R.B. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666–674.
    1. Oranje A.P., Chosidow O., Sacchidanand S., Todd G., Singh K., Scangarella N. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology. 2007;215:331–340.
    1. Paller A.S., Mancini A.J. 3rd ed. Elsevier; Philadelphia: 2006. Hurwitz clinical pediatric dermatology: a textbook of skin disorders of childhood and adolescence; pp. 366–367.
    1. Parish L.C., Jorizzo J.L., Breton J.J., Hirman J.W., Scangarella N.E., Shawar R.M. Topical retapamulin ointment (1%, wt⁄wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial. J Am Acad Dermatol. 2006;55:1003–1013.
    1. Popovich K.J., Hota B. Treatment and prevention of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Dermatol Ther. 2008;21:167–179.
    1. Raju V., Mongkolrattanothai K., Mankin P., Gray B. P11 poster presented at: 2008 Annual Conference on Antimicrobial Resistance. 2008. Surveillance for mupirocin resistance among MRSA clinical isolates.
    1. Rist T., Parish L.C., Capin L.R., Sulica V., Bushnell W.D., Cupo M.A. A comparison of the efficacy and safety of mupirocin cream and cephalexin in the treatment of secondarily infected eczema. Clin Exp Dermatol. 2002;27:14–20.
    1. Rittenhouse S., Biswas S., Broskey J., McCloskey L., Moore T., Vasey S. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob Agents Chemother. 2006;50:3882–3885.
    1. Rortveit S., Rortveit G. Impetigo in epidemic and nonepidemic phases: an incidence study over 4(1⁄2) years in a general population. Br J Dermatol. 2007;157:100–105.
    1. Silverberg N., Block S. Uncomplicated skin and skin structure infections in children: diagnosis and current treatment options in the United States. Clin Pediatr (Phila) 2008;47:211–219.
    1. Spellberg B., Powers J.H., Brass E.P., Miller L.G., Edwards J.E., Jr. In antimicrobial drug development: implications for the future. Clin Infect Dis. 2004;38:1279–1286.
    1. Steer A.C., Danchin M.H., Carapetis J.R. Group A streptococcal infections in children. J Paediatr Child Health. 2007;43:203–213.
    1. Traczewski M.M., Brown S.D. Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent. Antimicrob Agents Chemother. 2008;52:3863–3867.
    1. Wolter D.J., Tenover F.C., Goering R.V. Allelic variation in genes encoding Panton-Valentine leukocidin from community-associated Staphylococcus aureus. Clin Microbiol Infect. 2007;13:827–830.
    1. Woodford N., Afzal-Shah M., Warner M., Livermore D.M. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin. J Antimicrob Chemother. 2008;62:766–768.
    1. Yan K., Madden L., Choudhry A.E., Voigt C.S., Copeland R.A., Gontarek R.R. Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrob Agents Chemother. 2006;50:3875–3881.
    1. Yang L.P., Keam S.J. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs. 2008;68:855–873.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel